PharmaMar and Jazz Pharma positive top-line results from the Phase III clinical trial evaluating Zepzelca (lurbinectedin) in ...

Commit Biologics has named Mikkel Wandahl Pedersen as CSO. Pedersen, with over 20 years in immuno-oncology, previously led ...

Polish clinical-stage biotech Molecure has signed an exclusive licensing agreement with Ocean Biomedical based in Providence, ...

US clinical-stage genetic meds company MeiraGTx Holdings has released positive top-line data from its clinical bridging study ...

Johnson & Johnson (NYSE: JNJ) has reported revenue of $22.5 billion for the third quarter of 2024, a 5.2% increase ...

Novartis halted its Phase II IPF trial for LTP001, citing non-safety reasons. This move aligns with its strategy to ...

Eli Lilly (NYSE: LLY) plans to invest $206M to expand its Suzhou, China site for Type 2 diabetes and obesity drugs. The ...

Akeso Biopharma (HKEX: 9926) raised $250M via share placement, boosting cash reserves to over $1B. Funds will fast-track ...

Almirall has completed the decentralized EU regulatory procedure for efinaconazole (Jublia) for onychomycosis. The final step ...

French biopharma company Inventiva has announced financing of immediately 94.1 million euros ($103 million) and up to 348 ...

Amgen has reported positive Phase III results for Uplinza (inebilizumab-cdon) in treating generalized myasthenia gravis (gMG). The trial met key endpoints, showing significant improvement compared to ...

US pharma major Eli Lilly has released new data demonstrating more patients with moderately to severely active Crohn's ...